Replies to post #223835 on Biotech Values

[DewDiligence]

AGTC—Given the foregoing, you think they have a decent chance to show efficacy in the XLRP program?

Let me answer your question with a question: Did AGTC highlight the distinction in animal models between XLRS and XLRP before or after the XLRS failure?

[DewDiligence]

BIIB acquires NITE for $25.50/sh cash—a 68% premium to Friday’s close:

https://globenewswire.com/news-release/2019/03/04/1745678/0/en/Biogen-Announces-Agreement-to-Acquire-Nightstar-Therapeutics-to-Establish-Clinical-Pipeline-of-Gene-Therapy-Candidates-in-Ophthalmology.html

The nominal deal value is $877M.